The Russian Direct Investment Fund (RDIF), Singapore’s Asian American Medical Group (AAMG), and JSC Rusatom Healthcare, a subsidiary of ROSATOM, have agreed to jointly develop a nuclear medicine center in Iskandar Puteri, Malaysia. The agreement was signed on the sidelines of ASEAN Summit, ROSATOM’s webpage reports.
The proposed project involves the creation of a modern medical institution specializing in the diagnosis and treatment of cancer. The center, neighboring Singapore, will include departments specializing in radionuclide diagnostics, radionuclide therapy, radiation therapy and a cyclotron based radiochemistry facility among others.
The project will combine the financial resources of RDIF and ROSATOM and technical expertise of ROSATOM – which specialises in domestic and international promotion of Russian nuclear technology for medicine – with AAMG, a healthcare specialist based in Singapore.
“The agreement signed shows high demand for Russian medical technologies on the rapidly developing markets of the Asia-Pacific region that we consider today as core markets for us”, Denis Cherednichenko, CEO of JSC Rusatom Healthcare, said.